HomeAbout

TL;DR CNBC


FDA approves Eli Lilly's tirzepatide for weight loss, paving way for wider use of blockbuster drug - TL;DR CNBC

FDA approves Eli Lilly's tirzepatide for weight loss, paving way for wider use of blockbuster drug

Publishing timestamp: 2023-11-08 12:39:13


Summary

The FDA has approved Eli Lilly's tirzepatide drug for weight loss, allowing for wider use of the medication. The drug has already been approved for the treatment of Type 2 diabetes, but this new approval allows it to be used for chronic weight management in adults who are obese or overweight. The approval establishes Eli Lilly as a competitor in the obesity drug market, which is projected to be a $100 billion industry by 2030. The increased use of these drugs raises questions about their impact on various industries.


Sentiment: POSITIVE

Tickers: LLYNOVO.B-DK

Keywords: united statesbreaking newsbusiness newsscienceeli lilly and cohealth care industrybiotech and pharmaceuticalsbusinessbiotechnologybreaking news: businessnovo nordisk a/ssocial issuespharmaceuticals

Source: https://www.cnbc.com/2023/11/08/fda-approves-eli-lilly-drug-tirzepatide-for-obesity.html


Developed by Leo Phan